-
The State Food and Drug Administration Revises the Instructions for Mouse Nerve Growth Factor for Injection
Time of Update: 2021-03-26
On March 23, the State Food and Drug Administration issued an announcement on the revision of the instructions for mouse nerve growth factor for injection, and decided to revise the instructions for mouse nerve growth factor for injection [adverse reactions], [precautions] and medications for special populations.
-
The most compact superconducting cyclotron proton therapy system was successfully developed
Time of Update: 2021-03-26
Schematic diagram of the most compact domestically produced superconducting cyclotron proton therapy system (data picture) As a new type of radiotherapy technology, proton therapy has the advantages of good therapeutic effect, small side effects, and quick recovery of patients.
-
Hebei Province: Strengthening the supervision and inspection of medical expenses and prohibiting large prescriptions
Time of Update: 2021-03-26
Standardize the interactive process of doubtful points—strengthen the effect of agreement clauses and indicator constraints, and include priority use of medical insurance catalog drugs (medical consumables), control of the proportion of self-pay, prohibition of inducing drugs to be purchased out of hospitals, and issuing large prescriptions in violation of regulations, etc.
-
7 new domestically produced Class 1 anti-ED drugs are coming, and Yangtze River sprints for the first time!
Time of Update: 2021-03-26
The fourth domestic anti-ED oral PDE-5 inhibitor strikes, Haisco will win the first imitation A few days ago, Sichuan Haisco entered the administrative examination and approval stage with imitation 3 types of avanafil tablets, which is expected to be approved in the near future.
-
Consumables in the eight regions of Henan have been bargained to start mass production
Time of Update: 2021-03-26
Medical Network News on March 25 Bargaining prices for supplies in eight regions On March 24, according to the news from Huazhao Equipment Network, the Xinxiang City Drugs and Medical Consumables Alliance Centralized Procurement Platform issued the "Notice on Online Quotations for the Centralized Procurement of Medical Consumables Alliance of Eight Cities (Counties) including Xinxiang City, Henan Province".
-
Pfizer said an oral new crown treatment drug has entered clinical trials
Time of Update: 2021-03-26
On March 24th, 23rd local time in the United States, the pharmaceutical company Pfizer announced on its official website that the oral new crown treatment drug PF-07321332 has entered the phase 1b clinical trial phase.
-
Arikayce approved in Japan: the first drug to treat nontuberculous mycobacterial lung disease caused by MAC
Time of Update: 2021-03-26
The study was carried out in patients with refractory NTM lung disease caused by MAC, and the results showed that the study reached the primary endpoint: at the 6th month of treatment, compared with a guideline-based multi-drug regimen (MDR), Arikayce once a day Combined treatment with MDR can significantly increase the conversion rate of sputum culture (p<0.
-
Daiichi Sankyo mRNA vaccine DS-5670 Phase I/II clinical trial in Japan begins immunization
Time of Update: 2021-03-26
Recently, Daiichi Sankyo announced that the Phase I/II clinical trial of the novel coronavirus pneumonia (COVID-19) mRNA vaccine (DS-5670) in Japan has begun to vaccinate subjects.
Just recently, Moderna announced that its new-generation vaccine mRNA-1283 has been immunized in the first phase of clinical trials for the first batch of subjects.
-
Macau suspends vaccination of mRNA COVID-19 vaccine today due to defective packaging
Time of Update: 2021-03-26
The vaccine (valid until June 2021) is related to the packaging defects of the vial caps.
Baintech and Fosun Pharma have initiated investigations into the cause of the problem and must immediately suspend the vaccination.
-
Hisun Pharmaceutical: Epirubicin Hydrochloride for Injection passed the consistency evaluation of generic drugs
Time of Update: 2021-03-26
On March 23, Hisun Pharmaceutical announced that the company's epirubicin hydrochloride for injection has passed the quality and efficacy consistency evaluation of generic drugs.
On May 5, 2019, the State Food and Drug Administration accepted the company's application for the consistency evaluation of epirubicin hydrochloride for injection.
-
Novo Nordisk's high-dose semaglutide treatment application for diabetes is rejected by the FDA
Time of Update: 2021-03-26
0 mg once a week for treatment 2 Application for label extension for type-diabetes.
Although more information needs to be included in the resubmission, Novo Nordisk stated that the company believes that the completed clinical trial projects are sufficient to support semaglutide's label extension application.
-
Health Commission: 9 new confirmed cases, all imported from abroad
Time of Update: 2021-03-26
The latest situation of the novel coronavirus pneumonia epidemic as of 24:00 on March 22 The latest situation of the novel coronavirus pneumonia epidemic as of 24:00 on March 22 The
-
Circadian rhythm regulation mechanism of insulin sensitivity
Time of Update: 2021-03-26
Scientists reveal the circadian regulation mechanism of insulin sensitivity Scientists reveal the circadian regulation mechanism of insulin sensitivity Scientists reveal the circadi
-
Physiological regulation mechanism of "dawn phenomenon" in diabetic patients
Time of Update: 2021-03-26
According to reports, the study reveals the regulation mechanism of insulin sensitivity rhythm in glucose metabolism, not only explaining physiological phenomena, but also providing mechanism explanations and treatment suggestions for the "dawn phenomenon" that plagues diabetic patients.
-
How should traditional Chinese medicine companies spin off traditional Chinese medicines and transform them?
Time of Update: 2021-03-26
On March 22, Livzon Pharmaceutical announced that it plans to acquire 40% of Tianjin Tongrentang held by Tasly Holding Group as a financial investor for 724 million yuan.
-
A complete analysis of the development of Shanghai's hospital drug market in 2020
Time of Update: 2021-03-26
Figure 5 The growth rate of different therapeutic areas in the Shanghai hospital drug market in 2020 Medical Network, March 24th, this issue of HMAS medical institution market analysis system in-depth deconstruction of the Shanghai hospital drug market in 2020: under the influence of the epidemic and large-scale procurement, how will the hospital market at all levels and categories perform in 2020?
-
6681 pharmaceutical companies were notified that multiple provinces have successively issued notices
Time of Update: 2021-03-26
According to the "Guiding Opinions of the National Medical Security Administration on Establishing a Medical Price and Recruitment Credit Evaluation System", the center organized platform-related pharmaceutical companies to submit the "Pharmaceutical Enterprise Price and Marketing Behavior Credit Commitment".
-
U.S. research shows that children have stronger responses to new coronavirus antibodies than adults
Time of Update: 2021-03-26
The researchers narrowed the scope of the study to 85 children and 3648 adults who tested positive for the new crown, and further assessed their IgG antibody levels.
-
Conba: 1mg finasteride tablets passed the consistency evaluation of generic drugs
Time of Update: 2021-03-26
The sales of 1mg finasteride in the medical terminal market in 2019 was 47.
In 2019, the sales revenue of Hangzhou Kangenbei 1mg finasteride tablets was RMB 2.
73 million in research and development for the consistency evaluation of 1 mg finasteride tablets.
-
Shanghai passed local legislation: Chinese medicine is included in public health emergency management system
Time of Update: 2021-03-26
Encourage pharmaceutical manufacturers, operators of Chinese medicinal materials and Chinese medicinal pieces, medical institutions, and industry associations to establish an information traceability system in accordance with relevant laws, regulations and technical standards.
